Forest Ray

2 weeks ago | 360dx.com | Forest Ray

NEW YORK – A new low-cost tuberculosis (TB) test that requires no lab facilities and little specialist training might be able to help fill healthcare gaps in remote and low-resource settings. The Lab-in-a-Tube TB (LIT-TB) test is being developed by scientists at Tulane University, who published the results of a pilot study of the device yesterday in Science Translational Medicine.

3 weeks ago | 360dx.com | Forest Ray

NEW YORK – As Republican legislators in the US Congress look to slash Medicaid, the Rare Disease Advisory Council (RDAC) of Minnesota thinks that it has found a way to improve Medicaid access for newborns with rare diseases. Along with several collaborators, the Minnesota RDAC has proposed a bill, SF 1175, that would make children automatically –– or presumptively, in legal phrasing –– eligible for Medicaid disability coverage based on the results of newborn screening (NBS).

1 month ago | alsnewstoday.com | Marisa Wexler |Patricia Inacio |Forest Ray |Mary Chapman

A bipartisan team of lawmakers in the U.S. House of Representatives and Senate is pushing for legislation to help ensure that spouses of veterans who die from amyotrophic lateral sclerosis (ALS) have access to benefits. The Justice for ALS Veterans Act was introduced in the House by Brian Fitzpatrick, a Republican who represents Pennsylvania’s first district, and Chris Pappas, a Democrat from New Hampshire’s first district.

1 month ago | 360dx.com | Forest Ray

NEW YORK – Korean cancer diagnostics firm IMBDx is advancing its AlphaLiquid sequencing-based liquid biopsy technology for multiple applications including lung cancer therapy guidance and multi-cancer early detection, with an eye toward clinical guidelines inclusion and regulatory approval in Korea and elsewhere in East Asia.

2 months ago | 360dx.com | Forest Ray

NEW YORK – Vietnamese diagnostics firm Gene Solutions is preparing to expand commercialization of its SPOT-MAS multi-cancer early detection (MCED) test following the recent publication of a clinical validation study that showed strong sensitivity and negative predictive value in a cancer screening setting.